Lilly & Novo: Why the GLP-1 Rally Just Stumbled? | Valuebot Deep Dives

Euphoria turned to red screens. Eli Lilly and Novo Nordisk had been riding a rocket of blockbuster GLP-1 drug sales, dominating diabetes and obesity treatments—but suddenly the market flipped. What triggered the dip? Was it trial results, pharmacy benefit managers, competition, or regulatory headwinds? In this episode of The Deep Dive, we break down the numbers, the nuances, and the headlines to uncover why the market suddenly hit pause on two of the sector’s brightest stars. From soaring sales and shifting market share to the subtle cues investors can’t ignore, we go beyond the hype to understand what really matters—and what it means for the future of GLP-1. Strap in: it’s a rollercoaster you don’t want to miss.